Alvarado-Ortiz E, de la Cruz-Lopez K, Becerril-Rico J, Sarabia-Sanchez M, Ortiz-Sanchez E, Garcia-Carranca A
Front Cell Dev Biol. 2021; 8:607670.
PMID: 33644030
PMC: 7905058.
DOI: 10.3389/fcell.2020.607670.
Suchankova J, Legartova S, Ruckova E, Vojtesek B, Kozubek S, Bartova E
Histochem Cell Biol. 2017; 148(3):239-255.
PMID: 28397142
DOI: 10.1007/s00418-017-1567-3.
Wagner P, Hoever M, Appel K, Knochel W, Montenarh M
Rouxs Arch Dev Biol. 2017; 204(3):198-202.
PMID: 28305960
DOI: 10.1007/BF00241273.
Lopez Valverde G, Garcia Martin E, Larrosa Poves J, Polo Llorens V, Mateos J, Pablo Julvez L
PLoS One. 2016; 11(6):e0156317.
PMID: 27248495
PMC: 4889128.
DOI: 10.1371/journal.pone.0156317.
Yang J, Han D, Liang Q, Zhao J, Hao S, Ma X
World J Gastroenterol. 2016; 3(4):213-7.
PMID: 27053867
PMC: 4806235.
DOI: 10.3748/wjg.v3.i4.213.
Germline mutations of TP53 gene in breast cancer.
Damineni S, Rao V, Kumar S, Ravuri R, Kagitha S, Rao Dunna N
Tumour Biol. 2014; 35(9):9219-27.
PMID: 24929325
DOI: 10.1007/s13277-014-2176-6.
The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy.
Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S
Iran J Med Sci. 2012; 37(1):3-8.
PMID: 23115424
PMC: 3470295.
Study of mutations in p53 tumour suppressor gene in human sporadic breast cancers.
Makwane N, Saxena A
Indian J Clin Biochem. 2012; 24(3):223-8.
PMID: 23105839
PMC: 3453316.
DOI: 10.1007/s12291-009-0042-x.
Overexpression of p53 protein in human tumors.
Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M
Med Mol Morphol. 2012; 45(3):115-23.
PMID: 23001293
DOI: 10.1007/s00795-012-0575-6.
What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia.
Sulong S, Yusoff A, Zainuddin N, Abdullah J, Pannatil J, Jaafar H
Malays J Med Sci. 2012; 11(1):37-43.
PMID: 22977358
PMC: 3438149.
TP53 status and response to treatment in breast cancers.
Varna M, Bousquet G, Plassa L, Bertheau P, Janin A
J Biomed Biotechnol. 2011; 2011:284584.
PMID: 21760703
PMC: 3114547.
DOI: 10.1155/2011/284584.
Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry.
Scotcher J, Clarke D, Weidt S, Mackay C, Hupp T, Sadler P
J Am Soc Mass Spectrom. 2011; 22(5):888-97.
PMID: 21472523
DOI: 10.1007/s13361-011-0088-x.
The history of p53. A perfect example of the drawbacks of scientific paradigms.
Soussi T
EMBO Rep. 2010; 11(11):822-6.
PMID: 20930848
PMC: 2966958.
DOI: 10.1038/embor.2010.159.
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.
Allain D
J Mol Diagn. 2008; 10(5):383-95.
PMID: 18687797
PMC: 2518733.
DOI: 10.2353/jmoldx.2008.070161.
Biochemical and functional evidence of p53 homology is inconsistent with molecular phylogenetics for distant sequences.
Fernandes A, Atchley W
J Mol Evol. 2008; 67(1):51-67.
PMID: 18560747
DOI: 10.1007/s00239-008-9124-2.
Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas.
Chang H, Yoo B, Kim S, Lee B, Kim W
Pathol Oncol Res. 2007; 13(4):326-35.
PMID: 18158568
DOI: 10.1007/BF02940312.
Ubiquitination and degradation of mutant p53.
Lukashchuk N, Vousden K
Mol Cell Biol. 2007; 27(23):8284-95.
PMID: 17908790
PMC: 2169174.
DOI: 10.1128/MCB.00050-07.
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer.
Villiard E, Brinkmann H, Moiseeva O, Mallette F, Ferbeyre G, Roy S
BMC Evol Biol. 2007; 7:180.
PMID: 17903248
PMC: 2072957.
DOI: 10.1186/1471-2148-7-180.
Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.
Kamata H, Mitani S, Fujiwara M, Aoki N, Okada S, Mori S
Clin Exp Med. 2007; 7(2):39-46.
PMID: 17609875
DOI: 10.1007/s10238-007-0124-0.
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch L, Myhre S, Langerod A, Bergamaschi A, Geisler S, Lonning P
Mol Cancer. 2006; 5:47.
PMID: 17054774
PMC: 1636663.
DOI: 10.1186/1476-4598-5-47.
